logo-white

Abacus Medicine Pharma Services provides tailored commercialisation solutions for rare disease medicines in European markets.

Icon_Intro_SCD

Commercial Partnerships

In partnering with developers of innovative therapies, we tailor bespoke commercialisation solutions to bring the next generation of rare disease treatments into European markets. 

Combining decades of cross-functional industry expertise with the strong supply chain backbone of the Abacus Medicine Group, we offer true end-to-end commercialisation solutions to drive pan-European drug launches on our partners’ behalf.

Our Functional Areas

Contact the Commercial Partnerships team today

By combining decades of cross-functional industry experience with a resilient supply chain, we are in a position to deliver unique and impactful solutions in true partnership.

Resources

Case studies

Icon_Intro_SCD

Case Study CP0001

Multi market EU launch, promotion and distribution. 

Read our case study on how Abacus Medicine Pharma Services has developed a multi market access strategy for a client to successfully launch, promote, and distribute a rare disease product in 10 EU countries. 

Icon_Intro_SCD

Case Study CP0002

Simplyfying medicine access and growth in the Nordics.

Read our case study on how Abacus Medicine Pharma Services has helped several clients identify a larger potential for sales growth and operational effectiveness. 

Articles

Although orphan drugs are developed to address the unmet medical needs of rare disease patients, traditional launch strategies have failed to deliver widespread access. But is there a lucrative yet underserved market and patient population hidden just outside of the EU-5?

Read article.

Partnership models are becoming increasingly important when launching a drug. But when does it make sense to outsource, and when should you keep commercialisation inhouse?

Read article.

From telehealth to decentralised trials, the entire healthcare industry has realised the true value of digitalisation in recent years. Medical affairs teams are no exception. Here, we discuss the benefits and challenges of engaging medical professionals on digital channels.

Read article.

The joint health technology assessment (HTA) procedure was a hot topic at the World Orphan Drug Congress – Europe (WODC-EU) in Barcelona last month, and opinions were mixed.

Read article.

It is never too early in the product lifecycle to start developing a market access and pricing and reimbursement strategy, particularly when navigating the complex landscape of the European region.

Read article.

This Rare Disease Day, we look at the role increased awareness and improved pharmaceutical market conditions can play in closing the treatment inequality gap for rare disease patients.

Read article.

Cross-border cooperation is growing stronger in Europe, with key clusters such as Benelux and the Nordics accelerating joint procurement agreements in order to improve medicine access and increase negotiating power.

Read article.

Nordic healthcare providers are leading the momentum in enhancing ESG considerations. We examine the regional developments that will provide a competitive edge to pharma manufacturers.

Read article.

Pricing and reimbursement of pharmaceuticals is changing in Sweden, with prices lower than average as a result of growing cost containment strategies. Here’s what you need to know.

Read article.

The Nordics are a well-known powerhouse of pharmaceutical innovation and production. But what opportunities do the region’s own pharma markets offer industry players, and what do marketing authorisation holders need to know when bringing new medicines to these countries?

Read article.

Ensuring equitable access to medicines is a key challenge for many governments, particularly those of smaller nations. Pharmaceutical Technology reviews the data and explores European initiatives to improve the situation.

Read article.

Benelux offers much potential for companies distributing innovative medicines, but they may need to surmount hurdles such as the region’s complex and lengthy reimbursement systems.

Read article.

Contact the Commercial Partnerships team